Insider Selling: Natera (NASDAQ:NTRA) CFO Sells 23,948 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 23,948 shares of Natera stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52. Following the completion of the transaction, the chief financial officer directly owned 99,776 shares in the company, valued at $23,421,418.24. The trade was a 19.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $190.64, for a total transaction of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The shares were sold at an average price of $191.16, for a total transaction of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total value of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $196.77, for a total value of $148,561.35.

Natera Stock Performance

Natera stock traded up $0.13 during trading hours on Thursday, reaching $242.91. 971,052 shares of the stock were exchanged, compared to its average volume of 950,311. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The stock has a market cap of $33.60 billion, a P/E ratio of -106.07 and a beta of 1.62. The firm’s 50 day moving average is $233.44 and its 200 day moving average is $190.60.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.26) earnings per share. Equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NTRA. Piper Sandler upped their target price on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Evercore ISI upped their price target on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 price objective for the company in a research note on Monday, October 27th. Finally, BTIG Research lifted their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

Institutional Trading of Natera

Large investors have recently made changes to their positions in the stock. Sound Income Strategies LLC grew its holdings in shares of Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after buying an additional 45 shares in the last quarter. Savvy Advisors Inc. lifted its stake in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after buying an additional 46 shares during the period. Siemens Fonds Invest GmbH boosted its position in Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the last quarter. BOKF NA grew its stake in Natera by 1.9% in the 3rd quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after acquiring an additional 69 shares during the period. Finally, Silvant Capital Management LLC grew its stake in Natera by 0.5% in the 3rd quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock worth $2,171,000 after acquiring an additional 70 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.